Home・Stock List・Relay Therapeutics Inc

Relay Therapeutics Inc

Closed

SectorHealthcare

19.61 -0.15

Buy Sell

Overview

Share price change

24h

Current

Min

18.48

Max

19.8

Key metrics
By Trading Economics
Income	-18M -73M
Sales	-4M 3M
EPS	-0.41
Profit margin	-2,443.033
Employees	193
EBITDA	-15M -73M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.1% upside

Dividends
By Acuity
Next Earnings	5 Nov 2026

Market Stats
By TradingEconomics
Market Cap	1.6B 4.1B
Previous open	19.76
Previous close	19.61

News Sentiment

By Acuity

50%

168 / 340 Healthcare

Relay Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Aug 2026, 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 Aug 2026, 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 Aug 2026, 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 Aug 2026, 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 Jul 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 Jul 2026, 17:36 UTC

Correlated Moves

News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

29 Jul 2026, 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

28 Jul 2026, 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

27 Jul 2026, 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

22 Jul 2026, 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

21 Jul 2026, 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

20 Jul 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Peer Comparison

Price change

Relay Therapeutics Inc Forecast

Price Target

By TipRanks

28.1% upside

12 Months Forecast

Average 25.3 USD 28.1%

High 31 USD

Low 20 USD

Based on 12 Wall Street analysts offering 12 month price targets forRelay Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Relay Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

168 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.